Breast cancer stories

Apr 17, 2026

Datopotamab Deruxtecan Nearly Doubles Survival in Triple-Negative Breast Cancer Trial

Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.

Apr 17, 20261 source

00

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 20262 sources